Mounjaro Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Mounjaro Market Trends and Insights

Rising Type 2 Diabetes Burden and Earlier Treatment Initiation

The mounjaro market continues to draw strength from the expanding global diabetes population, but the larger commercial shift comes from earlier use of high-efficacy agents in the treatment pathway rather than from prevalence alone. The IDF Diabetes Atlas reported 589 million adults living with diabetes in 2025, with 42.8% of cases still undiagnosed, which leaves a large untreated pool that can move into drug therapy as screening improves.^{[1]International Diabetes Federation, “IDF Diabetes Atlas 11th Edition 2025, Global Diabetes Data and Insights,” IDF Diabetes Atlas, diabetesatlas.org} The Mounjaro market is benefiting because treatment practice is moving away from delayed escalation, and dual GIP and GLP-1 therapy is being considered earlier for patients who need glycemic control with parallel weight benefit. SURPASS-PEDS added another layer to this shift by showing efficacy and safety in children and adolescents with Type 2 Diabetes, which opens a new prescribing group that had limited high-efficacy options before 2025. This means the mounjaro market can grow faster than the underlying diagnosed population because more eligible patients are reaching tirzepatide earlier in the care sequence.

Superior Dual GIP and GLP-1 Efficacy Versus Single-Pathway Therapies

The mounjaro market is also being supported by head-to-head clinical evidence that strengthens tirzepatide’s position against competing incretin therapies. SURMOUNT-5 showed that tirzepatide was superior to semaglutide in reducing body weight and waist circumference over 72 weeks, which gave prescribers and payers comparative data that had been missing in this class.^{[2]Ania M. Jastreboff et al., “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity,” New England Journal of Medicine, nejm.org} The mechanistic case is reinforced by published clinical reviews showing that tirzepatide’s dual receptor activity creates a broader metabolic effect than a single-pathway GLP-1 therapy. A 2025 meta-analysis further supported better weight loss and glycemic outcomes for tirzepatide versus several comparators, which makes formulary preference decisions more defensible for payers. The mounjaro market, therefore, gains not only from patient demand but also from stronger evidence that can shift institutional prescribing patterns in a more durable way.

Label Expansion Into Obesity and Obstructive Sleep Apnea

The mounjaro market has moved beyond a single-disease profile because tirzepatide now addresses obesity-related conditions that bring in new specialist channels. The FDA approved tirzepatide as the first prescription medicine for moderate to severe obstructive sleep apnea in adults with obesity in December 2024, which created a treatment route that did not previously exist in this setting.^{[3]U.S. Food and Drug Administration, “FDA Approves First Medication for Obstructive Sleep Apnea,” FDA Press Announcements, fda.gov} That decision matters because obesity, sleep apnea, and Type 2 Diabetes often overlap in the same patient, so a single prescription can now sit across more than one clinically recognized need. SURMOUNT-OSA also showed improvements beyond airway events, including systolic blood pressure and patient-reported outcomes, which supports broader clinical acceptance in this pathway. The Mounjaro market is therefore expanding through a wider referral network that now includes sleep medicine and pulmonary specialists in addition to endocrinology and primary care.

Cross-Condition Use Potential in Cardiometabolic Care Pathways

The mounjaro market is increasingly shaped by evidence that tirzepatide fits into broader cardiometabolic management rather than standing as a diabetes-only or obesity-only therapy. SURPASS-CVOT confirmed noninferior cardiovascular protection versus dulaglutide and also showed a statistically significant 16% reduction in all-cause mortality, which gives the drug relevance in treatment discussions beyond glycemic control alone. The SUMMIT trial added to that position by showing reduced risk of cardiovascular death or worsening heart failure events in patients with heart failure with preserved ejection fraction and obesity. A 2025 review in Therapeutic Advances in Cardiovascular Disease described tirzepatide as a therapy emerging across metabolic, cardiorenal, and heart failure settings, which supports a multi-specialty prescribing future. As a result, the Mounjaro market is moving into care pathways where cardiologists and heart failure specialists can influence uptake alongside traditional metabolic prescribers.

Premium Monthly Cost and Coverage Restrictions

The mounjaro market still faces a large conversion gap between clinical eligibility and commercial access, especially where obesity treatment is not broadly reimbursed. Lilly’s own self-pay channel is evidence of that gap because the company priced single-dose vials at USD 349 to USD 499 per month to reach patients outside standard coverage pathways. This structure helps the Mounjaro market reach motivated cash-pay patients, but it also shows that mainstream payer support is not yet wide enough to absorb demand at scale through ordinary pharmacy benefit routes. Access conditions are also uneven across indications, because diabetes treatment generally faces a stronger reimbursement base than obesity treatment, which limits how quickly obesity demand can be monetized in community care settings. The mounjaro market can therefore maintain strong patient interest while still losing part of its reachable volume when monthly cost remains the main barrier.

Compounded or Off-Label Substitution Pressure in Shortage Cycles

The mounjaro market also carries residual friction from the period when supply shortages pushed some patients toward compounded alternatives. The FDA stated in December 2024 that the tirzepatide shortage had been resolved and set end dates for routine compounding tied to shortage conditions, which was an important step toward re-centering branded supply. Even with that change, the mounjaro market still has to win back patients who were introduced to lower-cost substitute channels during the shortage window and may not immediately return to the brand. Lilly’s expanded vial offering through LillyDirect is a direct response because it gives self-pay patients a legal brand option across all approved doses and reduces the price gap versus compounded products. This means substitution pressure is lower than it was during supply disruption, but the Mounjaro market still needs sustained brand access and dose availability to fully neutralize that behavior.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Indication: Weight Management Accelerates While T2D Anchors the Base

Type 2 diabetes held 56.03% of the mounjaro market size in 2025, which kept it as the main revenue base even as newer use cases expanded more quickly. Chronic weight management is projected to grow at 35.84% CAGR through 2031, making it the fastest-moving indication in the mounjaro market as obesity prescribing spreads into broader outpatient settings. The mounjaro market still depends on the diabetes indication for commercial stability because hospital formularies, specialist protocols, and existing treatment pathways were built around glycemic management first. That base gives Lilly a dependable core while newer obesity-linked channels add incremental volume on top of established use.

The second growth layer comes from label broadening and referral diversification. FDA approval for obstructive sleep apnea in adults with obesity created a new channel where pulmonologists and sleep specialists can refer or prescribe tirzepatide, which expands the Mounjaro market beyond the traditional diabetes and obesity clinic base. Pediatric evidence from SURPASS-PEDS also matters because it opens an early-stage opportunity in youth-onset Type 2 Diabetes, where treatment needs are rising and effective options are limited. The American Academy of Sleep Medicine has highlighted that tirzepatide became the first FDA-approved medication for sleep apnea, which reinforces how distinct this pathway is from historical device-led care. Taken together, these developments mean the Mounjaro market is growing through both a well-established base indication and newer referral sources that can keep patient inflow strong over the forecast period.

By Dosage Form: Vial Channel Disrupts the Prefilled-Pen Status Quo

Single-dose pen accounted for 60.18% of the Mounjaro market size in 2025, reflecting its established fit with hospital, specialty-clinic, and nurse-led injection workflows. That leadership position is tied to provider familiarity and the convenience of a prefilled device in routine diabetes care. The Mounjaro market still leans on the pen format because it supports mainstream prescribing patterns and fits existing administration habits. At the same time, the single-dose vial is forecast to rise at 36.76% CAGR through 2031, which makes it the more disruptive format from a commercial standpoint.

The reason for that disruption is not the container alone, but the access model it enables. Lilly offered approved Zepbound single-dose vials through LillyDirect Self Pay Pharmacy Solutions at USD 349 to USD 499 per month, which created a lower-priced branded route for cash-pay patients and widened access beyond traditional insured dispensing. Lilly then extended that model through Walmart Pharmacy retail pick-up in October 2025, which reduced delivery friction while keeping the direct channel intact. This shift matters because the Mounjaro market can now capture patients who were priced out of conventional branded incretin access but are still willing to self-pay for therapy. The result is that format mix is becoming a commercial strategy issue, not just a device preference issue, within the mounjaro industry.

By Strength: High-Dose Dominance Reflects Clinical Titration Endpoints

The 15 mg strength represented 24.67% of segment revenue in 2025 and is forecast to rise at 32.57% CAGR through 2031, which made it the largest single dose within the six-step titration ladder. This pattern shows that the mounjaro market derives its strongest value from maintenance doses rather than from early initiation doses that patients pass through for a shorter period. Lower strengths remain essential because the treatment protocol requires stepwise titration, but they function more as pathway points than as the main long-duration revenue anchors. In practical terms, this keeps all strengths relevant while concentrating the highest commercial value toward the upper end of the ladder.

Strength mix also depends on how well patients stay on therapy long enough to reach and maintain higher doses. Lilly’s decision to make all 6 approved Zepbound vial doses available through LillyDirect reduced dose-access gaps and gave self-pay patients a more complete branded pathway from titration to maintenance. Real-world research published in 2026 showed that 1-year persistence among GLP-1 receptor agonist initiators improved sharply through the first half of 2024, which suggests that better availability and smoother access can materially improve continuity. As persistence improves, the Mounjaro market is likely to see a greater share of prescriptions settling into high-value maintenance strengths. That creates a reinforcing effect where better supply and access support higher realized value per treated patient over time.

By Distribution Channel: Online Channels Rewrite Pharmacy Economics

Retail pharmacies held 39.03% of revenue in 2025, which kept them as the largest dispensing route in the mounjaro market because insured diabetes patients were already tied to standard pharmacy benefit flows. Hospital Pharmacies remained important for inpatient initiation and specialist-managed care, where titration could be monitored in structured settings. The Mounjaro market also continued to depend on physical dispensing infrastructure because cold-chain handling and counseling are still central to injectable therapy use. Online pharmacies, however, are projected to grow at 33.94% CAGR through 2031 and are reshaping how self-pay access is organized.

That change is being driven by brand-controlled direct distribution rather than by generic e-commerce expansion alone. LillyDirect became a major entry point for self-pay Zepbound access, and Lilly stated that the platform accounted for a large share of new prescriptions before the Walmart pick-up extension broadened convenience further. The online route matters because the Mounjaro market can connect prescription generation, fulfillment, and patient follow-up more directly than in the legacy wholesale model. It also compresses the boundary between online and offline dispensing, since patients can begin through a digital path and still collect treatment through physical retail. This hybrid structure should allow the Mounjaro market to keep shifting toward higher online participation while preserving trust and access for patients who prefer store-based pickup.

By End User: Primary Care Migration Unlocks Population-Scale Prescribing

Hospitals accounted for 35.63% of revenue in 2025, which reflected their role as the most established setting for early formulary adoption, complex titration, and specialist oversight. Specialty clinics remained a second concentration point because endocrinology and metabolic centers were early users of tirzepatide in both diabetes and obesity care. The mounjaro market also includes long-term care facilities and research institutions, but those settings contribute smaller volumes and tend to carry more targeted clinical use. This leaves hospitals as the current anchor, while the broader volume opportunity sits elsewhere.

Outpatient and primary care centers are forecast to grow at 34.74% CAGR through 2031, showing that the mounjaro market is migrating from specialist-led adoption into wider community prescribing. Real-world evidence published in Diabetes, Obesity and Metabolism showed rising tirzepatide initiation outside specialist settings, with primary care emerging as the fastest-growing prescriber category for weight-management use. This shift is commercially important because population-scale expansion depends on generalist adoption rather than on limited specialist capacity. It also introduces a management challenge because primary care physicians often need more support with titration and gastrointestinal side-effect monitoring than specialty centers do. Even so, the Mounjaro market stands to benefit materially as routine outpatient care becomes a larger gateway for both initiation and longer-term follow-up in the mounjaro industry.

Geography Analysis

North America accounted for 39.28% of the mounjaro market share in 2025, which kept it as the largest regional contributor. The United States remained the regional core because it had the broadest commercial infrastructure for tirzepatide, the deepest branded obesity demand, and the most advanced direct-to-consumer channel development. Lilly reported USD 22.965 billion in U.S. Mounjaro revenue in FY2025, which showed how much of the global franchise was still concentrated in the domestic base. The region also benefited from the addition of the sleep apnea indication and from stronger availability after earlier supply constraints began to ease.

Asia-Pacific is forecast to grow at 36.04% CAGR through 2031, making it the fastest-expanding regional block in the Mounjaro market. The main reason is scale, because large diabetes populations and broad obesity need to create a much wider long-term treatment pool than most other regions can match. Lilly’s first-quarter 2026 results showed ex-U.S. Mounjaro revenue of USD 4.4 billion, up from USD 1.2 billion in the comparable period of 2025, which signals that international markets are now contributing at a much faster pace. The Mounjaro market in Asia-Pacific also benefits from a mix of mature and emerging demand centers, with established uptake in developed healthcare systems and growing launch momentum in large-volume countries. This makes Asia-Pacific the region where volume expansion is likely to outpace revenue realization most clearly as access broadens and pricing conditions become more varied.

Europe held a meaningful position in the 2025 mounjaro market, supported by established diabetes reimbursement and a large treated population across major Western markets. Growth is steadier in Europe because reimbursement review is generally more measured, especially for obesity use, even when clinical interest is strong. Lilly’s November 2025 decision to build a USD 3 billion oral medicine manufacturing facility in the Netherlands showed that the company views Europe as strategically important both for supply and for future platform expansion. Middle East and Africa, and South America remain earlier-stage opportunities in the Mounjaro market, with adoption still building from a smaller base. Their role in the forecast period is less about immediate share leadership and more about adding new pockets of demand as regulatory access and commercial infrastructure continue to improve.